InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.010 -0.005 (-33.33%)+
Announcement
Release
23 Oct 2025 8:37AM
Price at Release
$0.015
Full Release
download
Summary
Anatara Lifesciences Ltd, a developer of evidence-based health products focused on gastrointestinal conditions, provided updates for the quarter ending 30 September 2025. The company continued its Anti-Obesity Project, with pre-clinical studies progressing as scheduled. A government R&D tax incentive refund of $0.969 million was received, contributing to stable cash flows and allowing for the repayment of a short-term loan. The company appointed Dirk Van Dissel as a Non-Executive Director, overseeing a Board renewal process. Plans for a share placement to raise $1.2 million were also announced, with the first tranche already raising $0.403 million. The GaRP project, focused on gastrointestinal health, continued to advance with business development discussions underway. The company reported a cash balance of $0.239 million at the end of the quarter.
Key Points
  • Anti-Obesity Project pre-clinical studies are on schedule.
  • Received $0.969 million R&D tax incentive refund.
  • Dirk Van Dissel appointed as Non-Executive Director.
  • Share placement announced to raise $1.2 million.
  • GaRP project development and business discussions ongoing.
  • Cash at end of quarter: $0.239 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.